COL4A5_HUMAN,N804S,0.061,-,-,-
COL4A5_HUMAN,M810V,0.095,-,-,-
COL4A5_HUMAN,L853F,0.038,-,-,-
COL4A5_HUMAN,P865R,0.570,Gain of Methylation at P865 (Pr = 0.11 | P = 0.03), ELME000005|ELME000062|ELME000136|ELME000155|ELME000159|ELME000240,-
COL4A5_HUMAN,P873S,0.097,-,-,-
COL4A5_HUMAN,T937A,0.034,-,-,-
COL4A5_HUMAN,P946R,0.508,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K943 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K943 (Pr = 0.25 | P = 9.1e-03); Loss of Methylation at K943 (Pr = 0.24 | P = 2.5e-03), ELME000005|ELME000106|ELME000155,-
COL4A5_HUMAN,E968D,0.111,-,-,-
COL4A5_HUMAN,P999H,0.455,-,-,-
COL4A5_HUMAN,N1010D,0.083,-,-,-
COL4A5_HUMAN,T1028A,0.075,-,-,-
COL4A5_HUMAN,E1041K,0.071,-,-,-
COL4A5_HUMAN,D1064G,0.332,-,-,-
COL4A5_HUMAN,V1100M,0.061,-,-,-
COL4A5_HUMAN,P1129L,0.073,-,-,-
COL4A5_HUMAN,S1136N,0.065,-,-,-
COL4A5_HUMAN,E1147Q,0.147,-,-,-
COL4A5_HUMAN,N1191T,0.158,-,-,-
COL4A5_HUMAN,P1323R,0.332,-,-,-
COL4A5_HUMAN,L1389P,0.291,-,-,-
COL4A5_HUMAN,T1402I,0.048,-,-,-
COL4A5_HUMAN,S1456T,0.076,-,-,-
COL4A5_HUMAN,T1470S,0.163,-,-,-
COL4A5_HUMAN,V1483I,0.028,-,-,-
COL4A5_HUMAN,Q1550E,0.059,-,-,-
COL4A5_HUMAN,G603C,0.941,Loss of B-factor (Pr = 0.32 | P = 4.0e-03); Loss of Acetylation at K599 (Pr = 0.27 | P = 8.2e-03); Loss of Methylation at K599 (Pr = 0.22 | P = 4.8e-03), ELME000005|ELME000155,-
COL4A5_HUMAN,G295D,0.952,Loss of Acetylation at K296 (Pr = 0.31 | P = 3.8e-03); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K296 (Pr = 0.25 | P = 2.1e-03); Gain of SUMOylation at K299 (Pr = 0.23 | P = 0.02), ELME000093|ELME000271|ELME000278|PS00009,-
COL4A5_HUMAN,G198V,0.946,Loss of B-factor (Pr = 0.35 | P = 1.2e-03); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04), None,-
COL4A5_HUMAN,G1161R,0.946,Loss of B-factor (Pr = 0.31 | P = 6.2e-03); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K1166 (Pr = 0.22 | P = 4.6e-03); Loss of Acetylation at K1166 (Pr = 0.21 | P = 0.04); Gain of SUMOylation at K1166 (Pr = 0.21 | P = 0.03), None,-
COL4A5_HUMAN,G719E,0.953,Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Gain of SUMOylation at K715 (Pr = 0.23 | P = 0.02); Loss of Methylation at K715 (Pr = 0.22 | P = 4.6e-03); Loss of Acetylation at K715 (Pr = 0.21 | P = 0.04), ELME000005|ELME000155,-
COL4A5_HUMAN,G301R,0.935,Loss of Acetylation at K302 (Pr = 0.53 | P = 4.6e-04); Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Methylation at K296 (Pr = 0.26 | P = 1.7e-03); Gain of SUMOylation at K302 (Pr = 0.25 | P = 8.6e-03), ELME000102,-
COL4A5_HUMAN,G1149V,0.956,Loss of B-factor (Pr = 0.30 | P = 7.9e-03); Altered Metal binding (Pr = 0.13 | P = 0.03), None,-
COL4A5_HUMAN,G860R,0.955,Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000135,-
COL4A5_HUMAN,G292R,0.947,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Methylation at K288 (Pr = 0.28 | P = 9.0e-04); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K288 (Pr = 0.26 | P = 7.2e-03); Gain of Acetylation at K288 (Pr = 0.25 | P = 0.01), ELME000103,-
COL4A5_HUMAN,G849E,0.946,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Acetylation at K845 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K845 (Pr = 0.22 | P = 0.02); Loss of Methylation at K845 (Pr = 0.19 | P = 7.6e-03), ELME000005|ELME000155,-
COL4A5_HUMAN,G772A,0.922,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Acetylation at K768 (Pr = 0.27 | P = 8.0e-03); Gain of SUMOylation at K768 (Pr = 0.18 | P = 0.04); Gain of Methylation at K774 (Pr = 0.17 | P = 9.6e-03), ELME000146,-
COL4A5_HUMAN,G144R,0.948,Loss of B-factor (Pr = 0.29 | P = 0.02); Loss of Loop (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G129R,0.967,Gain of SUMOylation at K128 (Pr = 0.28 | P = 4.2e-03); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Acetylation at K128 (Pr = 0.20 | P = 0.04); Loss of Methylation at K128 (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N125 (Pr = 0.02 | P = 0.03), ELME000064|ELME000070|ELME000100|ELME000108|ELME000220|PS00005|PS00006,-
COL4A5_HUMAN,G292V,0.955,Loss of B-factor (Pr = 0.33 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K288 (Pr = 0.27 | P = 7.2e-03); Loss of Methylation at K288 (Pr = 0.27 | P = 1.2e-03); Loss of SUMOylation at K288 (Pr = 0.25 | P = 9.0e-03); Gain of Amidation at P294 (Pr = 0.01 | P = 1.0e-03), None,-
COL4A5_HUMAN,G1217D,0.946,Gain of Loop (Pr = 0.30 | P = 6.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K1222 (Pr = 0.18 | P = 0.01), None,-
COL4A5_HUMAN,G469E,0.915,Gain of Loop (Pr = 0.30 | P = 5.5e-03); Loss of Acetylation at K465 (Pr = 0.21 | P = 0.04); Loss of Methylation at K465 (Pr = 0.19 | P = 8.4e-03), None,-
COL4A5_HUMAN,G893A,0.940,Gain of Loop (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K895 (Pr = 0.26 | P = 5.9e-03); Loss of Acetylation at K895 (Pr = 0.24 | P = 0.02); Gain of Methylation at K895 (Pr = 0.20 | P = 4.5e-03), ELME000064|ELME000220,-
COL4A5_HUMAN,G1427W,0.955,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Methylation at K1423 (Pr = 0.24 | P = 2.7e-03), ELME000005|ELME000155|ELME000190,-
COL4A5_HUMAN,G500R,0.944,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q495 (Pr = 0.07 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G594S,0.745,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K599 (Pr = 0.25 | P = 0.01); Loss of Methylation at K599 (Pr = 0.19 | P = 7.7e-03); Gain of SUMOylation at K599 (Pr = 0.19 | P = 0.04), ELME000063|ELME000085|ELME000337,-
COL4A5_HUMAN,G875R,0.937,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of O-linked glycosylation at S879 (Pr = 0.11 | P = 0.05); Gain of Methylation at G875 (Pr = 0.10 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G475S,0.926,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), PS00005,-
COL4A5_HUMAN,G869E,0.911,Gain of Loop (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G545S,0.901,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K544 (Pr = 0.26 | P = 6.2e-03); Loss of Methylation at K544 (Pr = 0.19 | P = 8.4e-03); Loss of Ubiquitylation at K544 (Pr = 0.15 | P = 0.04); Gain of Proteolytic cleavage at D549 (Pr = 0.13 | P = 0.02), ELME000064|PS00006,-
COL4A5_HUMAN,G769V,0.959,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.28 | P = 6.2e-03); Gain of SUMOylation at K768 (Pr = 0.21 | P = 0.03); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000146,-
COL4A5_HUMAN,G595R,0.207,-,-,-
COL4A5_HUMAN,G1196R,0.924,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.29 | P = 8.3e-03); Gain of O-linked glycosylation at S1201 (Pr = 0.13 | P = 0.04), ELME000135,-
COL4A5_HUMAN,G653R,0.921,Loss of B-factor (Pr = 0.30 | P = 7.8e-03); Loss of Methylation at K652 (Pr = 0.25 | P = 1.9e-03); Gain of O-linked glycosylation at T658 (Pr = 0.12 | P = 0.04), ELME000100|ELME000108,-
COL4A5_HUMAN,G491E,0.904,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of O-linked glycosylation at S490 (Pr = 0.19 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q495 (Pr = 0.07 | P = 0.02), ELME000085|ELME000155|PS00008,-
COL4A5_HUMAN,G869V,0.941,, None,-
COL4A5_HUMAN,G769R,0.958,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Loop (Pr = 0.29 | P = 0.01); Gain of Acetylation at K774 (Pr = 0.27 | P = 6.6e-03); Gain of SUMOylation at K768 (Pr = 0.21 | P = 0.03); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000100|ELME000106|ELME000108|ELME000146,-
COL4A5_HUMAN,G1229C,0.957,Altered Disordered interface (Pr = 0.29 | P = 0.03), None,-
COL4A5_HUMAN,G887V,0.952,Gain of Acetylation at K885 (Pr = 0.22 | P = 0.02); Loss of Methylation at K885 (Pr = 0.20 | P = 6.2e-03); Gain of SUMOylation at K885 (Pr = 0.18 | P = 0.05); Gain of Ubiquitylation at K885 (Pr = 0.16 | P = 0.04), ELME000239,-
COL4A5_HUMAN,G138D,0.960,Gain of Loop (Pr = 0.27 | P = 0.04), ELME000136|ELME000159|ELME000197,-
COL4A5_HUMAN,G264D,0.963,Gain of Loop (Pr = 0.30 | P = 6.7e-03); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Methylation at R266 (Pr = 0.11 | P = 0.03), None,-
COL4A5_HUMAN,G1066R,0.939,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 7.6e-03); Gain of SUMOylation at K1065 (Pr = 0.19 | P = 0.04); Loss of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.05), ELME000100|ELME000108,-
COL4A5_HUMAN,G1235A,0.849,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000155,-
COL4A5_HUMAN,C451R,0.798,Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of O-linked glycosylation at S447 (Pr = 0.13 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G180R,0.955,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Phosphorylation at Y175 (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000135,-
COL4A5_HUMAN,G233S,0.882,Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of SUMOylation at K229 (Pr = 0.25 | P = 8.2e-03); Loss of Acetylation at K229 (Pr = 0.21 | P = 0.03); Loss of Methylation at K229 (Pr = 0.21 | P = 6.0e-03), ELME000147,-
COL4A5_HUMAN,G1363S,0.895,Gain of Phosphorylation at G1363 (Pr = 0.34 | P = 9.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S1365 (Pr = 0.16 | P = 0.03), ELME000136|ELME000159|ELME000239,-
COL4A5_HUMAN,G365V,0.941,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K370 (Pr = 0.25 | P = 9.0e-03); Loss of Acetylation at K370 (Pr = 0.21 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), ELME000133|ELME000155,-
COL4A5_HUMAN,G1066S,0.891,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.7e-03); Gain of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.04), None,-
COL4A5_HUMAN,G1179R,0.963,Loss of Loop (Pr = 0.30 | P = 6.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K1181 (Pr = 0.26 | P = 7.1e-03); Loss of Acetylation at K1181 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1181 (Pr = 0.19 | P = 7.5e-03); Gain of Pyrrolidone carboxylic acid at Q1180 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G594R,0.851,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Acetylation at K599 (Pr = 0.24 | P = 0.01); Loss of Methylation at K599 (Pr = 0.19 | P = 7.4e-03), ELME000137|ELME000146|ELME000337,-
COL4A5_HUMAN,G893S,0.948,Gain of Loop (Pr = 0.26 | P = 0.05); Loss of SUMOylation at K895 (Pr = 0.25 | P = 8.3e-03); Gain of Acetylation at K895 (Pr = 0.24 | P = 0.02); Loss of Methylation at K895 (Pr = 0.19 | P = 7.7e-03), ELME000053|ELME000064|ELME000220|PS00005,-
COL4A5_HUMAN,A28S,0.364,-,-,-
COL4A5_HUMAN,G289R,0.959,Loss of B-factor (Pr = 0.30 | P = 9.5e-03); Loss of Methylation at K288 (Pr = 0.28 | P = 9.1e-04); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Acetylation at K285 (Pr = 0.27 | P = 7.1e-03); Gain of SUMOylation at K288 (Pr = 0.27 | P = 5.1e-03), ELME000100|ELME000108,-
COL4A5_HUMAN,G144D,0.950,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G298S,0.928,Loss of Acetylation at K299 (Pr = 0.30 | P = 4.3e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K296 (Pr = 0.25 | P = 2.2e-03); Loss of SUMOylation at K299 (Pr = 0.22 | P = 0.02), ELME000100|ELME000108|ELME000271|ELME000278,-
COL4A5_HUMAN,G775D,0.961,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Acetylation at K774 (Pr = 0.25 | P = 0.01); Loss of Methylation at K774 (Pr = 0.15 | P = 0.02), None,-
COL4A5_HUMAN,G322V,0.958,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.30 | P = 9.2e-03); Gain of Phosphorylation at Y320 (Pr = 0.29 | P = 0.02); Loss of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000006,-
COL4A5_HUMAN,G1232S,0.918,Gain of Loop (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G902E,0.941,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G334S,0.851,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K330 (Pr = 0.25 | P = 0.01); Loss of Methylation at K330 (Pr = 0.24 | P = 2.8e-03); Loss of SUMOylation at K333 (Pr = 0.19 | P = 0.04), ELME000173,-
COL4A5_HUMAN,G811R,0.930,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G766D,0.953,Gain of Loop (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of Acetylation at K768 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K768 (Pr = 0.19 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G567A,0.924,, ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G624D,0.775,, ELME000155,-
COL4A5_HUMAN,G719V,0.962,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K715 (Pr = 0.22 | P = 4.8e-03); Loss of Acetylation at K715 (Pr = 0.21 | P = 0.04); Loss of SUMOylation at K715 (Pr = 0.19 | P = 0.04), ELME000005|ELME000155,-
COL4A5_HUMAN,G1182V,0.965,Loss of B-factor (Pr = 0.31 | P = 6.8e-03); Gain of SUMOylation at K1181 (Pr = 0.27 | P = 5.0e-03); Loss of Acetylation at K1181 (Pr = 0.20 | P = 0.04); Loss of Methylation at K1181 (Pr = 0.19 | P = 7.2e-03), ELME000005|ELME000155,-
COL4A5_HUMAN,G298D,0.952,Loss of Acetylation at K302 (Pr = 0.32 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K296 (Pr = 0.25 | P = 2.2e-03); Loss of SUMOylation at K299 (Pr = 0.22 | P = 0.02), ELME000100|ELME000108|ELME000271|ELME000278,-
COL4A5_HUMAN,C1638S,0.916,Altered Metal binding (Pr = 0.71 | P = 9.3e-04); Loss of Disulfide linkage at C1638 (Pr = 0.36 | P = 6.8e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000062|ELME000162|ELME000334,-
COL4A5_HUMAN,G1205C,0.953,Loss of B-factor (Pr = 0.33 | P = 3.1e-03); Loss of Methylation at K1204 (Pr = 0.32 | P = 4.4e-04); Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of Acetylation at K1204 (Pr = 0.23 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G722E,0.952,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), None,-
COL4A5_HUMAN,G1223V,0.956,Loss of B-factor (Pr = 0.33 | P = 3.1e-03); Loss of Methylation at K1222 (Pr = 0.18 | P = 9.6e-03), ELME000002,-
COL4A5_HUMAN,G1176R,0.972,Loss of SUMOylation at K1181 (Pr = 0.25 | P = 9.6e-03); Gain of Acetylation at K1181 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1181 (Pr = 0.19 | P = 7.6e-03), None,-
COL4A5_HUMAN,G1448R,0.957,Loss of B-factor (Pr = 0.29 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G1066D,0.937,Gain of Loop (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of Acetylation at K1062 (Pr = 0.24 | P = 0.01); Loss of Methylation at K1065 (Pr = 0.18 | P = 8.9e-03); Loss of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.05), None,-
COL4A5_HUMAN,G180E,0.947,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), None,-
COL4A5_HUMAN,G316D,0.949,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of Phosphorylation at Y320 (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.03); Gain of Sulfation at Y320 (Pr = 0.04 | P = 9.4e-03), ELME000155,-
COL4A5_HUMAN,G383R,0.919,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.26 | P = 0.05), ELME000135|ELME000155,-
COL4A5_HUMAN,G1006V,0.947,Loss of B-factor (Pr = 0.37 | P = 4.4e-04); Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K1008 (Pr = 0.25 | P = 1.9e-03), None,-
COL4A5_HUMAN,G973D,0.968,Gain of Loop (Pr = 0.30 | P = 4.7e-03); Gain of O-linked glycosylation at S978 (Pr = 0.14 | P = 0.03), None,-
COL4A5_HUMAN,G561R,0.944,Gain of SUMOylation at K560 (Pr = 0.28 | P = 4.1e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K557 (Pr = 0.23 | P = 0.02); Loss of Methylation at K557 (Pr = 0.18 | P = 9.6e-03), ELME000100|ELME000108,-
